SCHEMBL3094403

SCHEMBL3094403

COc1ccc(CC(O)CC(=O)c2ccccc2)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.58
ADRB2 P07550 1/20 0.55
ADRB1 P08588 1/20 0.55
ADRB3 P13945 1/20 0.55
HTT P42858 3/20 0.53
NPC1 O15118 1/20 0.53
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
POLB P06746 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TRPV1 Q8NER1 1/20 0.52
MMP1 P03956 3/20 0.51
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
CYP3A4 P08684 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
STAT3 P40763 1/20 0.47
ALDH1A1 P00352 3/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102764 0.88 LMNA (0.71) LDHAHTTNPC1LMNAKMT2A
SCHEMBL3097956 0.87 LMNA (0.54) LDHAHTTNPC1LMNAPOLB
SCHEMBL570575 0.83 LMNA (0.75) LDHAHTTNPC1LMNAL3MBTL1
SCHEMBL10829626 0.81 LDHA (0.61) LDHAADRB2ADRB1ADRB3HTT
SCHEMBL3102740 0.77 TRPA1 (0.59) NPC1TRPV1KMT2AMEN1CYP3A4
SCHEMBL6202582 0.77 ACHE (0.59) HTTNPC1LMNAKMT2AMEN1
SCHEMBL3102314 0.76 NPC1 (0.61) LDHANPC1L3MBTL1TDP1SMN1; SMN2
SCHEMBL17335485 0.76 LDHA (0.63) LDHAMMP1KMT2ACYP3A4ALDH1A1
SCHEMBL10028825 0.75 ADRB2 (0.66) LDHAADRB2ADRB1LMNANPSR1
SCHEMBL7513442 0.75 LDHA (0.76) LDHAHTTNPC1LMNAMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-09-30 US disclosed
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-09-30 US disclosed
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-09-30 US disclosed
WO-2009066008-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA (FI) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY HSD17B11, HSD17B7, CYP19A1 LDHA 1348/4885ADRB2 357/4885ADRB1 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.